Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

biotech

  • Home
  •  
  • biotech



  • Most Read
  • Latest Comments
  • Neuren secures European patent for drug aimed to treat incurable brain disorders
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Neuren secures European patent for drug aimed to treat incurable brain disorders
    • Satire

    Australia to close borders to Omicron Persei 8
    Public
  • Neuren secures European patent for drug aimed to treat incurable brain disorders
    • Opinion

    The New Criterion: will the listed sanitiser stocks clean up – or clean out – investors?
    Public
  • Neuren secures European patent for drug aimed to treat incurable brain disorders
    • Opinion

    Is this the most hated company on the ASX?
    Public
  • Neuren secures European patent for drug aimed to treat incurable brain disorders
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    • News

  • Holista Colltech banks on new partners to turn fortunes as food sales struggle
    Holista Colltech banks on new partners to turn fortunes as food sales struggle
    • News

  • Zelira Therapeutics nears clinical trial stage for Autism drug following positive FDA feedback
    Zelira Therapeutics nears clinical trial stage for Autism drug following positive FDA feedback
    • News

  • Neuren secures European patent for drug aimed to treat incurable brain disorders
    • News

    Neuren secures European patent for drug aimed to treat incurable brain disorders

    Australian biopharmaceuticals developer Neuren Pharmaceuticals (ASX: NEU) has been granted a patent from the European Patent Office covering NNZ-2591, a world-first drug being developed to treat three neurodevelopmental disorders which affect children, and are currently incurable.  The granting of the new patent is the third jurisdiction to do so for Neuren with the same application

    Read More
    Public
  • Australia’s green whistle pain relief winning over Europeans
    • News

    Australia’s green whistle pain relief winning over Europeans

    Carried and administered by Australian paramedics for decades, the green whistle pain reliever has been on the Australian market for years but clinical trials in Europe have now revealed Penthrox® to be a superior pain relief product than traditional treatments of morphine (IV), paracetamol, ketoprofen and NSAIDS.  Marketed as Penthrox® with the key ingredient of

    Read More
    Public
  • Immutep clinical trials deliver significant tumour shrinkage in late-stage cancer patients
    • News

    Immutep clinical trials deliver significant tumour shrinkage in late-stage cancer patients

    Australian biotech company Immutep (ASX: IMM, NASDAQ: IMMP) has delivered impressive Phase I clinical trial results for its TACTI-mel trial which has observed significant tumour size shrinkage in the majority of trial patients over the 12 month trial period.  The trials tested 24 patients with melanoma which were located in areas not capable of being

    Read More
    Public
  • Botanix highlight cannabinoid creams as major frontier to treat skin conditions acne, psoriasis & more
    • News

    Botanix highlight cannabinoid creams as major frontier to treat skin conditions acne, psoriasis & more

    Sufferers of skin conditions like acne, psoriasis and dermatitis could soon have effective cannabinoid therapeutics thanks to Botanix (ASX:BOT) and their synthetic cannabinoid trials.  Presenting at the International Cannabinoid Derived Pharmaceuticals (iCDP) Summit in Boston, the presentation titled Fact or Fiction, highlighted the effectiveness seen in their recently completed clinical trials to treat acne, and

    Read More
    Public
  • ResApp shares surge following European approval for smartphone-based respiratory diagnostics app
    • News

    ResApp shares surge following European approval for smartphone-based respiratory diagnostics app

    Med-tech developer ResApp Health (ASX: RAP) has received certification from European regulators for the world’s first smartphone-based respiratory diagnostics test.  ResAppDx-EU is a mobile app which can be used by medical clinicians to diagnose respiratory conditions including tract disease, croup, pneumonia, asthma and bronchiolitis.  “We are very excited about receiving our first regulatory approval for

    Read More
    Public
  • NeuroScientific Biopharmaceuticals make major breakthrough towards treating Alzheimer’s
    • News

    NeuroScientific Biopharmaceuticals make major breakthrough towards treating Alzheimer’s

    With the average person’s life expectancy rising, Alzheimer’s disease is emerging as a major health concern which can have devastating effects on an individual’s cognitive function. It leads to progressive loss of brain cells which later leads to loss of memory and has become a global menace, costing the world over US$818 billion in treatment

    Read More
    Public
  • «
  • ‹
  • 10
  • 11
  • 12

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.